CSL Seqirus Highlights Global Impact and Local Investment at Town Council Meeting
The world's largest cell-based influenza vaccine manufacturing site, showcased its significant global and local contributions.
Holly Springs, NC, Nov. 20, 2024 — CSL Seqirus, the world's largest cell-based influenza vaccine manufacturing site, showcased its significant global and local contributions during a presentation to the Holly Springs Town Council on November 19, 2024. Representing over 1,000 employees at its Holly Springs facility, the company detailed its advancements in pandemic preparedness, vaccine production, and community engagement.
Founded as part of a public-private partnership with the U.S. government, CSL Seqirus is a critical player in producing vaccines using innovative cell-based technology. Unlike traditional egg-based vaccine production, cell-based methods offer greater efficacy and faster manufacturing capabilities. The facility is responsible for producing millions of seasonal influenza vaccine doses annually and maintaining readiness to deliver 150 million pandemic flu vaccine doses within six months if required.
CSL Seqirus emphasized its focus on next-generation vaccines to improve public health outcomes. Approximately 200 of its Holly Springs employees are dedicated to research and development, ensuring the company remains at the forefront of medical advancements.
The Holly Springs facility has grown significantly since its establishment in 2007 and its acquisition from Novartis in 2014. The site now spans 700,000 square feet on 170 acres, and more than $1.2 billion has been invested in infrastructure, including additional research labs and production lines.
CSL Seqirus also highlighted its local impact, including strong partnerships with the Holly Springs Police and Fire Departments and community organizations. The company participates in STEM education initiatives at area schools, volunteer events, and other programs designed to enhance the local community.
During the meeting, CSL representatives shared that their manufacturing efforts support public health globally, with vaccines produced in Holly Springs reaching hundreds of millions across five continents. The facility is also certified as pandemic-ready by the U.S. government, bolstering the nation’s ability to respond to public health emergencies.
The presentation underscored CSL Seqirus’s dual role as a global health leader and a committed community partner in Holly Springs. Its continued investment in cutting-edge technology and local collaboration reflects its dedication to innovation and the town it calls home.